The U.S. is making an attempt to dam a proposed $26 billion acquisition of Horizon Therapeutics by biotech drug developer Amgen on antitrust grounds.
The Federal Trade Commission stated Tuesday that the deal, introduced in December, would give Amgen unfair leverage to dam competitors for Horizon medicines. The FTC stated the deal would entrench Horizon’s monopoly place on remedies for thyroid eye illness and persistent refractory gout.
Amgen didn’t instantly reply to a request by The Associated Press for remark.
The California firm stated in December that the acquisition would permit it to develop into uncommon illness remedies.
Horizon Therapeutics PLC, based mostly in Dublin, Ireland, develops potential remedies for autoimmune and extreme inflammatory illnesses. Its best-seller, Tepezza, is simply accredited within the United States and treats eye bulging and double imaginative and prescient from thyroid eye illness.
The FTC stated Tuesday that the deal would permit Amgen to make use of rebates on its present medication to strain invoice payers like pharmacy profit managers into favoring Tepezz and Krystexxa, a remedy for persistent refractory gout.
Content Source: www.washingtontimes.com